search
Back to results

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Primary Purpose

Chronic Graft Versus Host Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Carfilzomib
Laboratory Biomarker Analysis
Quality-of-Life Assessment
Questionnaire Administration
Sponsored by
Fred Hutchinson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Graft Versus Host Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of chronic GVHD according to National Institutes of Health (NIH) Consensus Criteria

    • May have either classic chronic GVHD or overlap subtype of chronic GVHD
  • Failure of at least one prior line of systemic immune suppressive therapy for management of chronic GVHD
  • Subject underwent transplantation at least 3 months prior to enrollment
  • Anticipated life expectancy >= 6 months
  • Alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal, unless due to chronic GVHD
  • Bilirubin =< 2 mg/dL, unless due to chronic GVHD
  • Absolute neutrophil count (ANC) >= 1.0 × 10^9/L
  • Hemoglobin >= 8 g/dL
  • Platelet count >= 50 × 10^9/L
  • Creatinine clearance (CrCl) >= 15 mL/minute, either measured or calculated
  • Signed informed consent in accordance with federal, local, and institutional guidelines
  • Females of childbearing potential (FCBP) must agree to a pregnancy test at study enrollment and to practice contraception during the study
  • Male subjects must agree to practice contraception during the study

Exclusion Criteria:

  • Evidence of recurrent or progressive underlying malignant disease
  • Pregnant or lactating females

  • Surgery within 21 days prior to enrollment

    • Does not include placement of venous access device, bone marrow biopsy, GVHD diagnostic biopsy, or other routine procedures in chronic GVHD or post-transplantation care

  • Uncontrolled infection within 14 days prior to enrollment

    • Infection treated with appropriate antimicrobial therapy and without signs of progression/treatment failure does not constitute an exclusion criterion
  • Documented human immunodeficiency virus (HIV) infection
  • Active hepatitis B or C infection
  • Documented unstable angina or myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities (unless subject has a pacemaker), left ventricular ejection fraction (LVEF) < 40%, history of torsade de pointe

  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment

    • Sustained systolic blood pressure > 160 or diastolic blood pressure > 100 despite medical therapy; sustained blood sugar > 300 despite medical therapy
    • Chronic hypertension or diabetes on appropriate medical therapy does not constitute an exclusion criterion

  • Non-hematologic malignancy within the past 3 years with the exception of:

    • Adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer
    • Carcinoma in situ of the cervix or breast
    • Prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels
    • Cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study
  • Significant neuropathy per Common Terminology Criteria for Adverse Events (CTCAE) version (ver.) 4.03 or current version (grade 3 and above, or grade 2 with pain) within 14 days prior to enrollment
  • History of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
  • Contraindication to all available herpes simplex virus (HSV)/varicella prophylactic antiviral drugs
  • Pleural effusions requiring thoracentesis, or ascites requiring paracentesis, within 14 days prior to enrollment
  • Any other clinically significant medical or psychological disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
  • New systemic immune suppressive agent added for the treatment of chronic GVHD within 2 weeks prior to enrollment
  • Treatment with a non-Food and Drug Administration (FDA) approved drug in the previous 4 weeks

Sites / Locations

  • Moffitt Cancer Center
  • Roswell Park Cancer Institute
  • Ohio State University Comprehensive Cancer Center
  • University of Pittsburgh Cancer Institute (UPCI)
  • Fred Hutch/University of Washington Cancer Consortium

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (carfilzomib)

Arm Description

Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Incidence of Adverse Events
according to National Cancer Institute CTCAE, version 4.03
Probability of Treatment Failure at 6mo
Kaplan-Meier estimate assessed at 6 months for treatment failure, defined as requirement of an additional line of systemic immune-suppressive therapy, recurrent malignancy, or death.

Secondary Outcome Measures

Complete Response Rate
Complete response (CR) at 6 months will be determined by both clinician-defined CR, as well as separately calculated according to the proposed response definitions of the NIH Consensus Conference.
Cumulative Incidence of Non-relapse Mortality and Primary Malignancy Relapse
The cumulative incidence of non-relapse mortality (defined as death in the absence of primary malignancy relapse after transplant) and relapse (defined as hematologic relapse or any unplanned intervention to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease after transplantation) will be estimated from time of study therapy initiation. These will be treated as competing-risk events, and estimated at 1 year.
Probability of Failure-free Survival at 1 Year
Kaplain-Meier estimate assessed at 1 year for failure-free survival, defined as absence of death from any cause, relapse, or addition of secondary immune-suppressive agents.
Impact of Proteasome Inhibition
The biologic impact of proteasome inhibition in the treatment of chronic GVHD will be assessed at baseline, 3 and 6 months. The association between biologic outcome measures and clinical parameters (response, treatment failure, mortality) will be studied.
Incidence of Discontinuation of All Systemic Immune-suppressive Therapies
The incidence of complete discontinuation of all systemic immune-suppressive therapies will be determined at 1 year.
Overall Response Rate
Overall response rate (ORR) (complete response + partial response) at 6 months will be determined by both clinician-defined categories of complete response and partial response, as well as separately calculated according to the proposed response definitions of the NIH Consensus Conference.
Probability of Overall Survival at 1 Year
Kaplan-Meier estimate assessed at 1 year for overall survival, defined as absence of death from any cause.
Treatment Success
Treatment success will be estimated at 1 year with a composite outcome of complete resolution of all reversible chronic GVHD manifestations, discontinuation of all systemic immune suppressive agents, and freedom from death or primary malignancy relapse after transplant.
Use of Additional Systemic Immune-suppressive Therapies
Addition of therapy after carfilzomib constitutes failure, could occur at any time from baseline to 12mo.
Symptoms as Measured by Patient Self-report--Short Form-36 (SF-36)
SF-36 subscales have min=0 and max=100; results given are actual scores at 12mo, with higher scores indicating higher quality of life.
Symptoms as Measured by Patient Self-report--Functional Assessment of Chronic Illness Therapy (FACT)
FACT-BMT subscales have various min/max, see below; results given are actual 12mo scores, with higher scores indicating better functioning. FACT physical well-being (0-28) FACT social/family well-being (0-28) FACT emotional well-being (0-24) FACT functional well-being (0-28) FACT Bone Marrow Transplant (BMT) subscale (0-40) FACT trial outcome index (0-96) FACT-General (G) (0-108) FACT-BMT total (0-148)
Symptoms as Measured by Patient Self-report--Human Activities Profile (HAP)
HAP subscales have min=0 and max=94; results given are actual 12mo scores, with higher scores indicating better functioning. Maximum Activity Score (MAS) is highest item number answered still doing. Represents highest oxygen demanding activity that respondent still performs. Adjusted Activity Score (AAS) is MAS minus total number of stopped doing responses below MAS. A measure of usual daily activities. Modified AAS is MAS minus total number of stopped doing responses below MAS but not penalized for not doing activities not permitted post transplant. The following items are not counted against the score:11,15,19,20,22,25,34,41,42,47,49,50,52,53,54,57,72,73,77,78.
Symptoms as Measured by Patient Self-report--Lee Chronic GVHD Symptom Scale
Lee symptom scale (LSS) has subscales with min=0, max=100; results given are 12mo scores, with higher numbers indicating higher symptom burden.

Full Information

First Posted
June 10, 2015
Last Updated
January 15, 2019
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02491359
Brief Title
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Official Title
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
November 12, 2015 (Actual)
Primary Completion Date
February 19, 2018 (Actual)
Study Completion Date
September 12, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.
Detailed Description
PRIMARY OBJECTIVE: I. Determine proportion of subjects with treatment failure by 6 months of carfilzomib therapy for chronic graft-versus-host disease (GVHD). SECONDARY OBJECTIVES: I. Determine 3 month overall (complete + partial), and complete response rate. II. Determine 6 month overall (complete + partial), and complete response rate. III. Report overall survival, non-relapse mortality, primary malignancy relapse, failure-free survival, treatment success, and discontinuation of immune suppression at 6 months and 1 year. IV. Examine functional outcome (2-minute walk test) and patient-reported outcomes (Lee Chronic GVHD Symptom Scale, quality of life [Short Form Health Survey (SF)-36, Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT) Questionnaire], Human Activity Profile [HAP]) at study enrollment, 6 months, and 1 year. V. Study biologic effects of proteasome inhibition. OUTLINE: Patients receive carfilzomib intravenously (IV) over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 3, 6, and 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Graft Versus Host Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (carfilzomib)
Arm Type
Experimental
Arm Description
Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
Carfilzomib
Other Intervention Name(s)
Kyprolis, PR-171
Intervention Description
Given IV
Intervention Type
Other
Intervention Name(s)
Laboratory Biomarker Analysis
Intervention Description
Correlative studies
Intervention Type
Other
Intervention Name(s)
Quality-of-Life Assessment
Other Intervention Name(s)
Quality of Life Assessment
Intervention Description
Ancillary studies
Intervention Type
Other
Intervention Name(s)
Questionnaire Administration
Intervention Description
Ancillary studies
Primary Outcome Measure Information:
Title
Incidence of Adverse Events
Description
according to National Cancer Institute CTCAE, version 4.03
Time Frame
Up to 30 days following completion of study treatment
Title
Probability of Treatment Failure at 6mo
Description
Kaplan-Meier estimate assessed at 6 months for treatment failure, defined as requirement of an additional line of systemic immune-suppressive therapy, recurrent malignancy, or death.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Complete Response Rate
Description
Complete response (CR) at 6 months will be determined by both clinician-defined CR, as well as separately calculated according to the proposed response definitions of the NIH Consensus Conference.
Time Frame
Up to 6 months
Title
Cumulative Incidence of Non-relapse Mortality and Primary Malignancy Relapse
Description
The cumulative incidence of non-relapse mortality (defined as death in the absence of primary malignancy relapse after transplant) and relapse (defined as hematologic relapse or any unplanned intervention to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease after transplantation) will be estimated from time of study therapy initiation. These will be treated as competing-risk events, and estimated at 1 year.
Time Frame
1 year
Title
Probability of Failure-free Survival at 1 Year
Description
Kaplain-Meier estimate assessed at 1 year for failure-free survival, defined as absence of death from any cause, relapse, or addition of secondary immune-suppressive agents.
Time Frame
1 year
Title
Impact of Proteasome Inhibition
Description
The biologic impact of proteasome inhibition in the treatment of chronic GVHD will be assessed at baseline, 3 and 6 months. The association between biologic outcome measures and clinical parameters (response, treatment failure, mortality) will be studied.
Time Frame
Up to 6 months
Title
Incidence of Discontinuation of All Systemic Immune-suppressive Therapies
Description
The incidence of complete discontinuation of all systemic immune-suppressive therapies will be determined at 1 year.
Time Frame
1 year
Title
Overall Response Rate
Description
Overall response rate (ORR) (complete response + partial response) at 6 months will be determined by both clinician-defined categories of complete response and partial response, as well as separately calculated according to the proposed response definitions of the NIH Consensus Conference.
Time Frame
6 months
Title
Probability of Overall Survival at 1 Year
Description
Kaplan-Meier estimate assessed at 1 year for overall survival, defined as absence of death from any cause.
Time Frame
1 year
Title
Treatment Success
Description
Treatment success will be estimated at 1 year with a composite outcome of complete resolution of all reversible chronic GVHD manifestations, discontinuation of all systemic immune suppressive agents, and freedom from death or primary malignancy relapse after transplant.
Time Frame
1 year
Title
Use of Additional Systemic Immune-suppressive Therapies
Description
Addition of therapy after carfilzomib constitutes failure, could occur at any time from baseline to 12mo.
Time Frame
1 year
Title
Symptoms as Measured by Patient Self-report--Short Form-36 (SF-36)
Description
SF-36 subscales have min=0 and max=100; results given are actual scores at 12mo, with higher scores indicating higher quality of life.
Time Frame
baseline
Title
Symptoms as Measured by Patient Self-report--Functional Assessment of Chronic Illness Therapy (FACT)
Description
FACT-BMT subscales have various min/max, see below; results given are actual 12mo scores, with higher scores indicating better functioning. FACT physical well-being (0-28) FACT social/family well-being (0-28) FACT emotional well-being (0-24) FACT functional well-being (0-28) FACT Bone Marrow Transplant (BMT) subscale (0-40) FACT trial outcome index (0-96) FACT-General (G) (0-108) FACT-BMT total (0-148)
Time Frame
baseline
Title
Symptoms as Measured by Patient Self-report--Human Activities Profile (HAP)
Description
HAP subscales have min=0 and max=94; results given are actual 12mo scores, with higher scores indicating better functioning. Maximum Activity Score (MAS) is highest item number answered still doing. Represents highest oxygen demanding activity that respondent still performs. Adjusted Activity Score (AAS) is MAS minus total number of stopped doing responses below MAS. A measure of usual daily activities. Modified AAS is MAS minus total number of stopped doing responses below MAS but not penalized for not doing activities not permitted post transplant. The following items are not counted against the score:11,15,19,20,22,25,34,41,42,47,49,50,52,53,54,57,72,73,77,78.
Time Frame
baseline
Title
Symptoms as Measured by Patient Self-report--Lee Chronic GVHD Symptom Scale
Description
Lee symptom scale (LSS) has subscales with min=0, max=100; results given are 12mo scores, with higher numbers indicating higher symptom burden.
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of chronic GVHD according to National Institutes of Health (NIH) Consensus Criteria May have either classic chronic GVHD or overlap subtype of chronic GVHD Failure of at least one prior line of systemic immune suppressive therapy for management of chronic GVHD Subject underwent transplantation at least 3 months prior to enrollment Anticipated life expectancy >= 6 months Alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal, unless due to chronic GVHD Bilirubin =< 2 mg/dL, unless due to chronic GVHD Absolute neutrophil count (ANC) >= 1.0 × 10^9/L Hemoglobin >= 8 g/dL Platelet count >= 50 × 10^9/L Creatinine clearance (CrCl) >= 15 mL/minute, either measured or calculated Signed informed consent in accordance with federal, local, and institutional guidelines Females of childbearing potential (FCBP) must agree to a pregnancy test at study enrollment and to practice contraception during the study Male subjects must agree to practice contraception during the study Exclusion Criteria: Evidence of recurrent or progressive underlying malignant disease Pregnant or lactating females Surgery within 21 days prior to enrollment Does not include placement of venous access device, bone marrow biopsy, GVHD diagnostic biopsy, or other routine procedures in chronic GVHD or post-transplantation care Uncontrolled infection within 14 days prior to enrollment Infection treated with appropriate antimicrobial therapy and without signs of progression/treatment failure does not constitute an exclusion criterion Documented human immunodeficiency virus (HIV) infection Active hepatitis B or C infection Documented unstable angina or myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities (unless subject has a pacemaker), left ventricular ejection fraction (LVEF) < 40%, history of torsade de pointe Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Sustained systolic blood pressure > 160 or diastolic blood pressure > 100 despite medical therapy; sustained blood sugar > 300 despite medical therapy Chronic hypertension or diabetes on appropriate medical therapy does not constitute an exclusion criterion Non-hematologic malignancy within the past 3 years with the exception of: Adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer Carcinoma in situ of the cervix or breast Prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels Cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study Significant neuropathy per Common Terminology Criteria for Adverse Events (CTCAE) version (ver.) 4.03 or current version (grade 3 and above, or grade 2 with pain) within 14 days prior to enrollment History of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib) Contraindication to all available herpes simplex virus (HSV)/varicella prophylactic antiviral drugs Pleural effusions requiring thoracentesis, or ascites requiring paracentesis, within 14 days prior to enrollment Any other clinically significant medical or psychological disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent New systemic immune suppressive agent added for the treatment of chronic GVHD within 2 weeks prior to enrollment Treatment with a non-Food and Drug Administration (FDA) approved drug in the previous 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephanie Lee
Organizational Affiliation
Fred Hutch/University of Washington Cancer Consortium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Roswell Park Cancer Institute
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Facility Name
Ohio State University Comprehensive Cancer Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
University of Pittsburgh Cancer Institute (UPCI)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Fred Hutch/University of Washington Cancer Consortium
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

We'll reach out to this number within 24 hrs